LINC01856

Across TCGA pan-cancer cohorts, LINC01856 RNA differs between tumor and matched normal tissue in 4 of 18 cancer types tested, making tumor–normal expression one of LINC01856’s most consistent transcriptional readouts.

The strongest signal is observed in breast invasive carcinoma (BRCA), where LINC01856 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types LINC01856 is over-expressed in tumor, although a few such as THCA and LUAD show the opposite, repressed pattern.

BRCA, THCA, and LUAD are the cancer types where LINC01856 tumor–normal differential expression is most reproducible.

RNA tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in LINC01856 RNA (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
BRCA	All	All	+0.111	.017	3	view →
THCA	All	II,III,IV	−0.025	.045	1	view →
LUAD	Female	All	−0.016	.013	1	view →
COAD	Female	All	−0.006	.037	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 4 strongest of 4 lineages.

LINC01856–BRCA

Open the BRCA breakdown →